Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

NCT05461794 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

96

Enrollment

INDUSTRY

Sponsor class

Stopped Due to modification of company strategy.

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Sitravatinib
DRUG: Tislelizumab
DRUG: Docetaxel
DRUG: Irinotecan

Sponsor

BeiGene